This report examines approaches to budgeting that would distinguish expenditures for investment in physical capital, education, and research and development from other expenditures.
The opening statement of Joseph Kile, CBO’s Director of Microeconomic Analysis, on the long-term solvency of the Highway Trust Fund before the Senate Committee on Environment and Public Works.
CBO assesses trends in spending for prescription drug research and development (R&D) and the introduction of new prescription drugs. CBO also examines factors that determine how much drug companies spend on R&D.
The federal budget deficit was $1.7 trillion in the first six months of fiscal year 2021, CBO estimates—almost $1 trillion more than the deficit recorded during the same period last year.
In this report, the latest in a quarterly series, CBO highlights its recent work and summarizes its work in progress.
CBO describes the key design considerations for a federally administered nongroup health insurance plan—often referred to as a public option—and some of their major implications.
CBO estimates that the effects on revenues and mandatory spending of laws enacted in 2020 will add $2.8 trillion to deficits from 2020 to 2030—the net result of a $634 billion reduction in revenues and a $2.2 trillion increase in outlays.
CBO updated its interactive tool that allows users to design options for increasing the minimum wage and to examine how they would affect earnings, employment, family income, and poverty.
This report provides CBO’s projections of the Army’s costs to acquire tanks and other ground combat vehicles through 2050. On the basis of the Army’s plans, those costs are projected to average about $5 billion annually.
The Navy’s shipyards have experienced significant delays in completing maintenance on submarines. In this report, CBO projects that required maintenance will continue to exceed the shipyards’ capacity and examines options to reduce delays.